Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Distribution: Plasma Protein Binding

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward.

Kidney international reports·2026

Same author

Perivascular fat, hypertension, and cardiovascular disease.

Kidney international·2026

Same author

French nephrologists’ practices in the management of anemia and iron deficiency in chronic kidney disease

Nephrologie & therapeutique·2026

Same author

Mechanism of reduced intestinal phosphate absorption by tenapanor: a hypothesis.

Clinical kidney journal·2026

Same author

Contribution of genetic variants to nephrolithiasis.

Kidney international·2025

Same author

A longitudinal analysis of haemoglobin levels and major cardiovascular events.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β₂-Microglobulin

Published on: March 10, 2021

Beta2-microglobulin.

Tilman B Drüeke¹, Ziad A Massy

¹Inserm Unit 845, Necker Medical School, University Paris-Descartes, Paris, France. tilman.drueke@inserm.fr

Seminars in Dialysis

|August 28, 2009

Summary

Beta2-microglobulin (beta2-M) is a key uremic toxin that accumulates in chronic kidney disease. While dialysis removes beta2-M, predialysis levels remain high, contributing to amyloidosis.

Area of Science:

Nephrology
Biochemistry
Internal Medicine

Background:

Beta2-microglobulin (beta2-M) is a middle molecule uremic toxin.
Serum beta2-M levels rise with chronic kidney disease progression, especially in end-stage renal disease.
High extracellular beta2-M contributes to dialysis-related amyloidosis.

Purpose of the Study:

To review the role of beta2-M in kidney disease.
To discuss the implications of beta2-M accumulation and removal.
To examine trends in beta2-M amyloidosis.

Main Methods:

Literature review on beta2-M in chronic kidney disease.
Analysis of beta2-M's role in dialysis-related amyloidosis.
Discussion of hemodialysis and hemodiafiltration efficacy.

More Related Videos

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins

Published on: August 7, 2014

Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry

Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry

Published on: June 26, 2019

Related Experiment Videos

Last Updated: Jun 20, 2026

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β₂-Microglobulin

Published on: March 10, 2021

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins

Published on: August 7, 2014

Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry

Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry

Published on: June 26, 2019

Main Results:

Beta2-M is a significant uremic toxin and a major component of dialysis-related amyloidosis.
Effective dialysis techniques reduce beta2-M, but predialysis levels persist.
The incidence of beta2-M amyloidosis may be decreasing or delayed.

Conclusions:

Beta2-M accumulation is a critical factor in dialysis-related amyloidosis.
Current dialysis methods improve but do not normalize predialysis beta2-M levels.
Long-term trends suggest a potential shift in the timing or prevalence of beta2-M amyloidosis.